Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Identifieur interne : 000C24 ( PubMed/Checkpoint ); précédent : 000C23; suivant : 000C25Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Auteurs : J J Knox [Canada] ; C H Barrios [Brésil] ; T M Kim [Corée du Sud] ; T. Cosgriff [États-Unis] ; V. Srimuninnimit [Thaïlande] ; K. Pittman [Australie] ; R. Sabbatini [Italie] ; S Y Rha [Corée du Sud] ; T W Flaig ; R D Page ; J T Beck [États-Unis] ; F. Cheung [République populaire de Chine] ; S. Yadav [Canada] ; P. Patel [Royaume-Uni] ; L. Geoffrois ; J. Niolat [France] ; N. Berkowitz ; M. Marker ; D. Chen ; R J Motzer [États-Unis]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.
DOI: 10.1093/annonc/mdx075
PubMed: 28327953
Affiliations:
- Australie, Brésil, Canada, Corée du Sud, France, Italie, Royaume-Uni, République populaire de Chine, Thaïlande, États-Unis
- Angleterre, Nottinghamshire, Ontario, Rio Grande do Sul, Région capitale de Séoul, État de New York
- Nottingham, Porto Alegre, Séoul, Toronto
- Université de Nottingham, Université de Toronto
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28327953Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.</title><author><name sortKey="Knox, J J" sort="Knox, J J" uniqKey="Knox J" first="J J" last="Knox">J J Knox</name><affiliation wicri:level="4"><nlm:affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Barrios, C H" sort="Barrios, C H" uniqKey="Barrios C" first="C H" last="Barrios">C H Barrios</name><affiliation wicri:level="3"><nlm:affiliation>PUCRS School of Medicine, Porto Alegre, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>PUCRS School of Medicine, Porto Alegre</wicri:regionArea><placeName><settlement type="city">Porto Alegre</settlement><region type="state">Rio Grande do Sul</region></placeName></affiliation></author><author><name sortKey="Kim, T M" sort="Kim, T M" uniqKey="Kim T" first="T M" last="Kim">T M Kim</name><affiliation wicri:level="3"><nlm:affiliation>Internal Medicine, Seoul National University Hospital, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Internal Medicine, Seoul National University Hospital, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Cosgriff, T" sort="Cosgriff, T" uniqKey="Cosgriff T" first="T" last="Cosgriff">T. Cosgriff</name><affiliation wicri:level="1"><nlm:affiliation>Crescent City Research Consortium, Marrero, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Crescent City Research Consortium, Marrero</wicri:regionArea><wicri:noRegion>Marrero</wicri:noRegion></affiliation></author><author><name sortKey="Srimuninnimit, V" sort="Srimuninnimit, V" uniqKey="Srimuninnimit V" first="V" last="Srimuninnimit">V. Srimuninnimit</name><affiliation wicri:level="1"><nlm:affiliation>Internal Medicine, Siriraj Hospital, Mahidol University, Mahidol, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Internal Medicine, Siriraj Hospital, Mahidol University, Mahidol</wicri:regionArea><wicri:noRegion>Mahidol</wicri:noRegion></affiliation></author><author><name sortKey="Pittman, K" sort="Pittman, K" uniqKey="Pittman K" first="K" last="Pittman">K. Pittman</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medical Oncology, The Queen Elizabeth Hospital, Woodville</wicri:regionArea><wicri:noRegion>Woodville</wicri:noRegion></affiliation></author><author><name sortKey="Sabbatini, R" sort="Sabbatini, R" uniqKey="Sabbatini R" first="R" last="Sabbatini">R. Sabbatini</name><affiliation wicri:level="1"><nlm:affiliation>AOU Policlinico di Modena, Modena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>AOU Policlinico di Modena, Modena</wicri:regionArea><wicri:noRegion>Modena</wicri:noRegion></affiliation></author><author><name sortKey="Rha, S Y" sort="Rha, S Y" uniqKey="Rha S" first="S Y" last="Rha">S Y Rha</name><affiliation wicri:level="3"><nlm:affiliation>Yonsei Cancer Center, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Yonsei Cancer Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Flaig, T W" sort="Flaig, T W" uniqKey="Flaig T" first="T W" last="Flaig">T W Flaig</name><affiliation><nlm:affiliation>University of Colorado School of Medicine, Aurora.</nlm:affiliation><wicri:noCountry code="subField">Aurora</wicri:noCountry></affiliation></author><author><name sortKey="Page, R D" sort="Page, R D" uniqKey="Page R" first="R D" last="Page">R D Page</name><affiliation><nlm:affiliation>The Center for Cancer and Blood Disorders, Fort Worth.</nlm:affiliation><wicri:noCountry code="subField">Fort Worth</wicri:noCountry></affiliation></author><author><name sortKey="Beck, J T" sort="Beck, J T" uniqKey="Beck J" first="J T" last="Beck">J T Beck</name><affiliation wicri:level="1"><nlm:affiliation>Highlands Oncology Group, Fayetteville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Highlands Oncology Group, Fayetteville</wicri:regionArea><wicri:noRegion>Fayetteville</wicri:noRegion></affiliation></author><author><name sortKey="Cheung, F" sort="Cheung, F" uniqKey="Cheung F" first="F" last="Cheung">F. Cheung</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Queen Elizabeth Hospital, Hong Kong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Queen Elizabeth Hospital, Hong Kong</wicri:regionArea><wicri:noRegion>Hong Kong</wicri:noRegion></affiliation></author><author><name sortKey="Yadav, S" sort="Yadav, S" uniqKey="Yadav S" first="S" last="Yadav">S. Yadav</name><affiliation wicri:level="1"><nlm:affiliation>Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Saskatoon Cancer Center, University of Saskatchewan, Saskatoon</wicri:regionArea><wicri:noRegion>Saskatoon</wicri:noRegion></affiliation></author><author><name sortKey="Patel, P" sort="Patel, P" uniqKey="Patel P" first="P" last="Patel">P. Patel</name><affiliation wicri:level="4"><nlm:affiliation>Academic Division of Clinical Oncology, University of Nottingham, Nottingham, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Academic Division of Clinical Oncology, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation></author><author><name sortKey="Geoffrois, L" sort="Geoffrois, L" uniqKey="Geoffrois L" first="L" last="Geoffrois">L. Geoffrois</name><affiliation><nlm:affiliation>Department of Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre Lès Nancy.</nlm:affiliation><wicri:noCountry code="subField">Vandoeuvre Lès Nancy</wicri:noCountry></affiliation></author><author><name sortKey="Niolat, J" sort="Niolat, J" uniqKey="Niolat J" first="J" last="Niolat">J. Niolat</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma SAS, Rueil-Malmaison, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma SAS, Rueil-Malmaison</wicri:regionArea><wicri:noRegion>Rueil-Malmaison</wicri:noRegion><wicri:noRegion>Rueil-Malmaison</wicri:noRegion></affiliation></author><author><name sortKey="Berkowitz, N" sort="Berkowitz, N" uniqKey="Berkowitz N" first="N" last="Berkowitz">N. Berkowitz</name><affiliation><nlm:affiliation>Novartis Oncology, East Hanover.</nlm:affiliation><wicri:noCountry code="subField">East Hanover</wicri:noCountry></affiliation></author><author><name sortKey="Marker, M" sort="Marker, M" uniqKey="Marker M" first="M" last="Marker">M. Marker</name><affiliation><nlm:affiliation>Novartis Oncology, East Hanover.</nlm:affiliation><wicri:noCountry code="subField">East Hanover</wicri:noCountry></affiliation></author><author><name sortKey="Chen, D" sort="Chen, D" uniqKey="Chen D" first="D" last="Chen">D. Chen</name><affiliation><nlm:affiliation>Novartis Oncology, East Hanover.</nlm:affiliation><wicri:noCountry code="subField">East Hanover</wicri:noCountry></affiliation></author><author><name sortKey="Motzer, R J" sort="Motzer, R J" uniqKey="Motzer R" first="R J" last="Motzer">R J Motzer</name><affiliation wicri:level="2"><nlm:affiliation>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28327953</idno><idno type="pmid">28327953</idno><idno type="doi">10.1093/annonc/mdx075</idno><idno type="wicri:Area/PubMed/Corpus">000B48</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B48</idno><idno type="wicri:Area/PubMed/Curation">000B45</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B45</idno><idno type="wicri:Area/PubMed/Checkpoint">000B45</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.</title><author><name sortKey="Knox, J J" sort="Knox, J J" uniqKey="Knox J" first="J J" last="Knox">J J Knox</name><affiliation wicri:level="4"><nlm:affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Barrios, C H" sort="Barrios, C H" uniqKey="Barrios C" first="C H" last="Barrios">C H Barrios</name><affiliation wicri:level="3"><nlm:affiliation>PUCRS School of Medicine, Porto Alegre, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>PUCRS School of Medicine, Porto Alegre</wicri:regionArea><placeName><settlement type="city">Porto Alegre</settlement><region type="state">Rio Grande do Sul</region></placeName></affiliation></author><author><name sortKey="Kim, T M" sort="Kim, T M" uniqKey="Kim T" first="T M" last="Kim">T M Kim</name><affiliation wicri:level="3"><nlm:affiliation>Internal Medicine, Seoul National University Hospital, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Internal Medicine, Seoul National University Hospital, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Cosgriff, T" sort="Cosgriff, T" uniqKey="Cosgriff T" first="T" last="Cosgriff">T. Cosgriff</name><affiliation wicri:level="1"><nlm:affiliation>Crescent City Research Consortium, Marrero, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Crescent City Research Consortium, Marrero</wicri:regionArea><wicri:noRegion>Marrero</wicri:noRegion></affiliation></author><author><name sortKey="Srimuninnimit, V" sort="Srimuninnimit, V" uniqKey="Srimuninnimit V" first="V" last="Srimuninnimit">V. Srimuninnimit</name><affiliation wicri:level="1"><nlm:affiliation>Internal Medicine, Siriraj Hospital, Mahidol University, Mahidol, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Internal Medicine, Siriraj Hospital, Mahidol University, Mahidol</wicri:regionArea><wicri:noRegion>Mahidol</wicri:noRegion></affiliation></author><author><name sortKey="Pittman, K" sort="Pittman, K" uniqKey="Pittman K" first="K" last="Pittman">K. Pittman</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medical Oncology, The Queen Elizabeth Hospital, Woodville</wicri:regionArea><wicri:noRegion>Woodville</wicri:noRegion></affiliation></author><author><name sortKey="Sabbatini, R" sort="Sabbatini, R" uniqKey="Sabbatini R" first="R" last="Sabbatini">R. Sabbatini</name><affiliation wicri:level="1"><nlm:affiliation>AOU Policlinico di Modena, Modena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>AOU Policlinico di Modena, Modena</wicri:regionArea><wicri:noRegion>Modena</wicri:noRegion></affiliation></author><author><name sortKey="Rha, S Y" sort="Rha, S Y" uniqKey="Rha S" first="S Y" last="Rha">S Y Rha</name><affiliation wicri:level="3"><nlm:affiliation>Yonsei Cancer Center, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Yonsei Cancer Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Flaig, T W" sort="Flaig, T W" uniqKey="Flaig T" first="T W" last="Flaig">T W Flaig</name><affiliation><nlm:affiliation>University of Colorado School of Medicine, Aurora.</nlm:affiliation><wicri:noCountry code="subField">Aurora</wicri:noCountry></affiliation></author><author><name sortKey="Page, R D" sort="Page, R D" uniqKey="Page R" first="R D" last="Page">R D Page</name><affiliation><nlm:affiliation>The Center for Cancer and Blood Disorders, Fort Worth.</nlm:affiliation><wicri:noCountry code="subField">Fort Worth</wicri:noCountry></affiliation></author><author><name sortKey="Beck, J T" sort="Beck, J T" uniqKey="Beck J" first="J T" last="Beck">J T Beck</name><affiliation wicri:level="1"><nlm:affiliation>Highlands Oncology Group, Fayetteville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Highlands Oncology Group, Fayetteville</wicri:regionArea><wicri:noRegion>Fayetteville</wicri:noRegion></affiliation></author><author><name sortKey="Cheung, F" sort="Cheung, F" uniqKey="Cheung F" first="F" last="Cheung">F. Cheung</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Queen Elizabeth Hospital, Hong Kong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Queen Elizabeth Hospital, Hong Kong</wicri:regionArea><wicri:noRegion>Hong Kong</wicri:noRegion></affiliation></author><author><name sortKey="Yadav, S" sort="Yadav, S" uniqKey="Yadav S" first="S" last="Yadav">S. Yadav</name><affiliation wicri:level="1"><nlm:affiliation>Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Saskatoon Cancer Center, University of Saskatchewan, Saskatoon</wicri:regionArea><wicri:noRegion>Saskatoon</wicri:noRegion></affiliation></author><author><name sortKey="Patel, P" sort="Patel, P" uniqKey="Patel P" first="P" last="Patel">P. Patel</name><affiliation wicri:level="4"><nlm:affiliation>Academic Division of Clinical Oncology, University of Nottingham, Nottingham, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Academic Division of Clinical Oncology, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation></author><author><name sortKey="Geoffrois, L" sort="Geoffrois, L" uniqKey="Geoffrois L" first="L" last="Geoffrois">L. Geoffrois</name><affiliation><nlm:affiliation>Department of Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre Lès Nancy.</nlm:affiliation><wicri:noCountry code="subField">Vandoeuvre Lès Nancy</wicri:noCountry></affiliation></author><author><name sortKey="Niolat, J" sort="Niolat, J" uniqKey="Niolat J" first="J" last="Niolat">J. Niolat</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma SAS, Rueil-Malmaison, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma SAS, Rueil-Malmaison</wicri:regionArea><wicri:noRegion>Rueil-Malmaison</wicri:noRegion><wicri:noRegion>Rueil-Malmaison</wicri:noRegion></affiliation></author><author><name sortKey="Berkowitz, N" sort="Berkowitz, N" uniqKey="Berkowitz N" first="N" last="Berkowitz">N. Berkowitz</name><affiliation><nlm:affiliation>Novartis Oncology, East Hanover.</nlm:affiliation><wicri:noCountry code="subField">East Hanover</wicri:noCountry></affiliation></author><author><name sortKey="Marker, M" sort="Marker, M" uniqKey="Marker M" first="M" last="Marker">M. Marker</name><affiliation><nlm:affiliation>Novartis Oncology, East Hanover.</nlm:affiliation><wicri:noCountry code="subField">East Hanover</wicri:noCountry></affiliation></author><author><name sortKey="Chen, D" sort="Chen, D" uniqKey="Chen D" first="D" last="Chen">D. Chen</name><affiliation><nlm:affiliation>Novartis Oncology, East Hanover.</nlm:affiliation><wicri:noCountry code="subField">East Hanover</wicri:noCountry></affiliation></author><author><name sortKey="Motzer, R J" sort="Motzer, R J" uniqKey="Motzer R" first="R J" last="Motzer">R J Motzer</name><affiliation wicri:level="2"><nlm:affiliation>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28327953</PMID><DateCreated><Year>2017</Year><Month>03</Month><Day>22</Day></DateCreated><DateRevised><Year>2017</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.</ArticleTitle><Pagination><MedlinePgn>1339-1345</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdx075</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.</AbstractText><AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">Patients received either first-line everolimus followed by second-line sunitinib at progression (n = 238) or first-line sunitinib followed by second-line everolimus (n = 233). Secondary end points were combined first- and second-line progression-free survival (PFS), OS, and safety. The impacts of neutrophil lymphocyte ratio (NLR) and baseline levels of soluble biomarkers on OS were explored.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">At final analysis, median duration of exposure was 5.6 months for everolimus and 8.3 months for sunitinib. Median combined PFS was 21.7 months [95% confidence interval (CI) 15.1-26.7] with everolimus-sunitinib and 22.2 months (95% CI 16.0-29.8) with sunitinib-everolimus [hazard ratio (HR)EVE-SUN/SUN-EVE, 1.2; 95% CI 0.9-1.6]. Median OS was 22.4 months (95% CI 18.6-33.3) for everolimus-sunitinib and 29.5 months (95% CI 22.8-33.1) for sunitinib-everolimus (HREVE-SUN/SUN-EVE, 1.1; 95% CI 0.9-1.4). The rates of grade 3 and 4 adverse events suspected to be related to second-line therapy were 47% with everolimus and 57% with sunitinib. Higher NLR and 12 soluble biomarker levels were identified as prognostic markers for poor OS with the association being largely independent of treatment sequences.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Results of this final OS analysis support the sequence of sunitinib followed by everolimus at progression in patients with mRCC. The safety profiles of everolimus and sunitinib were consistent with those previously reported, and there were no unexpected safety signals.</AbstractText><AbstractText Label="Clinical Trials number" NlmCategory="UNASSIGNED">ClinicalTrials.gov identifier, NCT00903175.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knox</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrios</LastName><ForeName>C H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>PUCRS School of Medicine, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>T M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Internal Medicine, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosgriff</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Crescent City Research Consortium, Marrero, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srimuninnimit</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Internal Medicine, Siriraj Hospital, Mahidol University, Mahidol, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittman</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbatini</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>AOU Policlinico di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rha</LastName><ForeName>S Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Yonsei Cancer Center, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaig</LastName><ForeName>T W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Page</LastName><ForeName>R D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>The Center for Cancer and Blood Disorders, Fort Worth.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>J T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Highlands Oncology Group, Fayetteville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oncology, Queen Elizabeth Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Academic Division of Clinical Oncology, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geoffrois</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre Lès Nancy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niolat</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Novartis Pharma SAS, Rueil-Malmaison, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berkowitz</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Novartis Oncology, East Hanover.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marker</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Novartis Oncology, East Hanover.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Novartis Oncology, East Hanover.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motzer</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">everolimus</Keyword><Keyword MajorTopicYN="N">renal cell carcinoma</Keyword><Keyword MajorTopicYN="N">sequential targeted therapy</Keyword><Keyword MajorTopicYN="N">sunitinib</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28327953</ArticleId><ArticleId IdType="pii">3040903</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdx075</ArticleId><ArticleId IdType="pmc">PMC5452072</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Brésil</li><li>Canada</li><li>Corée du Sud</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>République populaire de Chine</li><li>Thaïlande</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Nottinghamshire</li><li>Ontario</li><li>Rio Grande do Sul</li><li>Région capitale de Séoul</li><li>État de New York</li></region><settlement><li>Nottingham</li><li>Porto Alegre</li><li>Séoul</li><li>Toronto</li></settlement><orgName><li>Université de Nottingham</li><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Berkowitz, N" sort="Berkowitz, N" uniqKey="Berkowitz N" first="N" last="Berkowitz">N. Berkowitz</name><name sortKey="Chen, D" sort="Chen, D" uniqKey="Chen D" first="D" last="Chen">D. Chen</name><name sortKey="Flaig, T W" sort="Flaig, T W" uniqKey="Flaig T" first="T W" last="Flaig">T W Flaig</name><name sortKey="Geoffrois, L" sort="Geoffrois, L" uniqKey="Geoffrois L" first="L" last="Geoffrois">L. Geoffrois</name><name sortKey="Marker, M" sort="Marker, M" uniqKey="Marker M" first="M" last="Marker">M. Marker</name><name sortKey="Page, R D" sort="Page, R D" uniqKey="Page R" first="R D" last="Page">R D Page</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Knox, J J" sort="Knox, J J" uniqKey="Knox J" first="J J" last="Knox">J J Knox</name></region><name sortKey="Yadav, S" sort="Yadav, S" uniqKey="Yadav S" first="S" last="Yadav">S. Yadav</name></country><country name="Brésil"><region name="Rio Grande do Sul"><name sortKey="Barrios, C H" sort="Barrios, C H" uniqKey="Barrios C" first="C H" last="Barrios">C H Barrios</name></region></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Kim, T M" sort="Kim, T M" uniqKey="Kim T" first="T M" last="Kim">T M Kim</name></region><name sortKey="Rha, S Y" sort="Rha, S Y" uniqKey="Rha S" first="S Y" last="Rha">S Y Rha</name></country><country name="États-Unis"><noRegion><name sortKey="Cosgriff, T" sort="Cosgriff, T" uniqKey="Cosgriff T" first="T" last="Cosgriff">T. Cosgriff</name></noRegion><name sortKey="Beck, J T" sort="Beck, J T" uniqKey="Beck J" first="J T" last="Beck">J T Beck</name><name sortKey="Motzer, R J" sort="Motzer, R J" uniqKey="Motzer R" first="R J" last="Motzer">R J Motzer</name></country><country name="Thaïlande"><noRegion><name sortKey="Srimuninnimit, V" sort="Srimuninnimit, V" uniqKey="Srimuninnimit V" first="V" last="Srimuninnimit">V. Srimuninnimit</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Pittman, K" sort="Pittman, K" uniqKey="Pittman K" first="K" last="Pittman">K. Pittman</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Sabbatini, R" sort="Sabbatini, R" uniqKey="Sabbatini R" first="R" last="Sabbatini">R. Sabbatini</name></noRegion></country><country name="République populaire de Chine"><noRegion><name sortKey="Cheung, F" sort="Cheung, F" uniqKey="Cheung F" first="F" last="Cheung">F. Cheung</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Patel, P" sort="Patel, P" uniqKey="Patel P" first="P" last="Patel">P. Patel</name></region></country><country name="France"><noRegion><name sortKey="Niolat, J" sort="Niolat, J" uniqKey="Niolat J" first="J" last="Niolat">J. Niolat</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000C24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28327953
|texte= Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28327953" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |